help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tajiri, Y.
Right arrow Articles by Grill, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tajiri, Y.
Right arrow Articles by Grill, V.
Endocrinology Vol. 138, No. 1 273-280
Copyright © 1997 by The Endocrine Society


ARTICLES

Long Term Effects of Aminoguanidine on Insulin Release and Biosynthesis: Evidence That the Formation of Advanced Glycosylation End Products Inhibits B Cell Function1

Yuji Tajiri, Christer Möller and Valdemar Grill

Department of Molecular Medicine, Endocrine and Diabetes Unit, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden; and the Department of Internal Medicine, University of Trondheim, Trondheim, Norway

Address all correspondence and requests for reprints to: Dr. Valdemar Grill, Department of Molecular Medicine, Endocrine and Diabetes Unit, Karolinska Hospital, S-17176 Stockholm, Sweden.


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Chronic hyperglycemia has adverse effects on B cell function. We investigated the possible role of advanced glycosylation end products (AGEs) in glucotoxicity. Rat islets were cultured at different glucose concentrations for 1–6 weeks in RPMI 1640. Culture was performed with or without aminoguanidine (AG), which is known to prevent AGE formation in other tissues. AGE-associated fluorescence (370 nm excitation and 440 nm emission) progressively increased during 6 weeks of culture at 38 mM, but not at 11 or 5.5 mM, glucose. The increase in fluorescence was significantly inhibited by AG. The effects of AG on insulin secretion were tested directly after the culture period as well as after a wash-out period of continued culture at 11 mM glucose in the absence of AG. The presence of AG during culture for 1 week at 38 mM glucose failed to affect basal release at 3.3 mM glucose or stimulated release at 27 mM glucose. AG was ineffective whether tested directly after the culture period or after wash-out. When the same culture conditions were prolonged for 6 weeks, culture with AG suppressed basal and stimulated insulin secretion after the culture period. However, after wash-out, previous AG treatment enhanced the insulin response to 27 mM glucose 2-fold compared to culture without AG (P < 0.01). Proinsulin and total protein biosyntheses in 38 mM glucose-cultured islets were increased 40–80% by AG after 6 weeks of culture, and this effect was similar after wash-out. Preproinsulin messenger RNA levels were significantly increased (P < 0.05) after 6 weeks of culture with AG. NG-Methyl-L-arginine, a nitric oxide synthase inhibitor, failed to mimic the effects of AG. The results indicate that the time-dependent beneficial effects of AG on insulin secretion and biosynthesis are related to inhibitory effects on AGE formation and that accumulation of islet AGEs could be important for glucotoxicity toward B cells.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
THE DIABETIC state impairs B cell function in both animals (1, 2) and man (3, 4). Evidence indicates that both hyperglycemia (2) and elevated FFA (5) are important for decreased function. One effect of hyperglycemia is indirect and coupled to excessive stimulation (6). This indirect effect of hyperglycemia is rapidly induced and rapidly reversible. However, direct effects of glucose (glucotoxicity), with longer latency of induction and reversal, are also possible and may be suspected because of the known potency of chronic hyperglycemia to cause diabetic complications.

The mechanisms by which chronic hyperglycemia causes diabetic complications, such as retinopathy, neuropathy, and nephropathy, are in part related to nonenzymatic glycation and its sequelae. Hyperglycemia gives rise to nonenzymatic glycation of proteins and other molecules. Nonenzymatic glycation alters the physical properties of key molecules inside and outside of cells. This could lead to dysregulation of important cellular processes. Glycated molecules can be altered further by the formation of advanced glycosylation end products (AGEs). This formation may have serious negative effects. AGEs have thus been associated with cellular damage in microvascular complications of diabetes (7).

The effects of aminoguanidine (AG) constitute major evidence for the importance of AGEs in diabetic complications. AG is a nucleophilic hydrazine compound that potently inhibits AGE formation (8, 9). Beneficial effects of AG on diabetic complications have been reported in vivo and in vitro (10, 11, 12, 13) and are associated with inhibitory effects on AGE formation (14, 15, 16).

It is not known whether AGEs are formed in pancreatic islets or to which extent AGEs influence pancreatic B cells. Evidence against an important role for AGEs comes from observations that AG adversely affects insulin release in rat pancreatic islets (14, 17). However, in the previous studies islets were either acutely exposed to AG (14) or cultured for a only short period (2 days) with AG (17). From current knowledge of the time course of AGE formation, a much longer exposure time is needed to demonstrate AGE effects and reversal thereof by AG (14, 15, 16). Also, a beneficial effect of AG related to its effect on AGEs could be overshadowed by a negative effect related to the drug per se.

We aimed to test whether the formation of islet AGEs is of importance for negative effects of high glucose on B cell function. Specifically, we wished to test 1) whether high glucose induces the formation of AGEs in pancreatic islets, 2) whether AG affects AGE formation in pancreatic islets, and 3) whether long term exposure to AG in high glucose-cultured islets is beneficial for B cell function.

For these purposes, we assessed AGE formation in islets by fluorescence and measured the effects of AG on this parameter. Furthermore, we evaluated the effects of AG on insulin secretion, insulin biosynthesis, and insulin messenger RNA (mRNA) from high glucose-cultured rat islets. We reasoned that AGE-related effects of AG would affect that part of B cell dysfunction that is not rapidly reversible; therefore, B cell functional parameters were evaluated after an overnight wash-out period. A wash-out period also served to eliminate short term negative effects of AG per se. To evaluate the participation of a recently demonstrated effect of AG on NO synthase (18, 19), we also tested the effects of NG-methyl-L-arginine (L-NMA), a potent NO synthase inhibitor, on insulin secretion.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials
AG, L-NMA, arginine hydrochloride, isobutylmethylxanthine, Histopaque, and PBS were purchased from Sigma Chemical Co. (St. Louis, MO). L-[4,5-3H]Leucine (62 Ci/mmol) was from Amersham International (Amersham, Aylesbury, UK). Undiluted guinea pig antiporcine insulin serum was obtained from ICN ImmunoBiologicals (Lisle, IL). Protein A-Sepharose CL-4B, Sephadex G-50 columns (nick column), and Dextran T-70 were purchased from Pharmacia (Uppsala, Sweden). Collagenase, ribonuclease A (RNase A), and RNase T1 were obtained from Boehringer Mannheim (Mannheim, Germany). [35S]UTP (1082 Ci/mmol) was purchased from DuPont-New England Nuclear (Boston, MA). Riboprobe Gemini II Core System, pGEM-3Zf(+), herring sperm DNA, RQ1 deoxyribonuclease I, and restriction enzymes (EcoRI and XbaI) were obtained from Promega Biotec (Madison, WI). GF/C filters were purchased from Whatman International (Maidstone, UK). RPMI 1640 medium, penicillin, streptomycin, and FCS were obtained from Life Technologies (Grand Island, NY). Tissue culture flasks were purchased from Nunc (Copenhagen, Denmark).

Animals
Female Wistar rats were obtained from B&K Universal (Stockholm, Sweden). At the time of experiments they weighed between 150–250 g. They had free access to tap water and a standard pelleted diet. They were exposed to a 12-h light (0600–1800 h), 12-h dark cycle. The experimental protocols were approved by the Stockholm ethical committee for research on animals.

Isolation of islets
Animals were killed by decapitation, and pancreatic islets were isolated by collagenase digestion as previously described (20). Collagenase was injected into the common bile duct at a concentration of 2 mg/ml in 10 ml Hanks’ solution containing 5.5 mM glucose. The pancreas was digested at 37 C for 20 min. The islets were partly separated from exocrine tissue using gradient centrifugation (700 x g, 20 min, 4 C) in Histopaque. Islets were transferred to RPMI 1640 medium containing 11 mM glucose, antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) and 10% FCS. Islets were cultured free floating at 37 C with an atmosphere of 5% CO2-95% air for 1–2 days (primary culture) to remove exocrine or other tissues.

Islet culture
After the period of primary culture, islets were selected under a stereomicroscope and transferred into 260-ml tissue culture flasks containing RPMI 1640 with the glucose concentrations described below and with or without AG (0.1 or 1 mM). Before being added to the culture medium, AG was dissolved in redistilled water at acidic condition (pH 3.0) and brought to the same pH as the culture medium (14). In one series of experiments, 0.1 mM L-NMA was used instead of AG. Islets were cultured for 1–6 weeks. Culture medium was exchanged every second day. At the end of a 1- or 6-week culture period, some islets of each group were cultured for an additional 24 h in RPMI with 11 mM glucose but without AG or L-NMA (wash-out period).

Measurement of AGE-associated fluorescence
Islets were cultured as described above in RPMI medium containing 5.5, 11, or 38 mM glucose with or without AG. After culture, islets (20 for each determination) were washed 3 times in PBS, then sonicated in 300 µl redistilled water. The sonicates were centrifuged at 10,000 x g for 10 min at 4 C, and fluorescence was measured in the supernatants, using excitation at 370 nm and emission at 440 nm (21) by SPEX-1681 0.22-m spectrometer (SPEX industries, Edison, NJ).

Islet volume
In some experiments islets cultured under different conditions were randomly selected, and perpendicular diameters were measured under a stereomicroscope. Diameters were averaged, and islet volume was calculated by the formula: islet volume (nl) = 4{pi}r3/3 x 10-6 (r = radian, microns) (22).

Insulin release
After the culture period, islets were preincubated at 37 C for 30 min in Krebs-Ringer bicarbonate (KRB) medium (23) with the following composition: 143 mM Na+, 5.8 mM K+, 2.5 mM Ca2+, 1.2 mM Mg2+, 124.1 mM Cl-, 1.2 mM PO43-, 1.2 mM SO42-, and 25 mM CO32-, pH 7.4, supplemented with 10 mM HEPES, 0.2% BSA (fraction IV, Sigma Chemical Co.), and 3.3 mM glucose. Islets were selected after preincubation in batches of three islets in 300 µl KRB containing either 3.3 or 27 mM glucose and, in some experiments, other additions. Final incubations were then carried out at 37 C for 60 min in a shaking water bath and an atmosphere of 95% O2-5% CO2. At the end of incubations, aliquots of the incubation medium were removed for assay of insulin concentrations. Islets that had been exposed to 3.3 mM glucose in final incubations were retrieved for the determination of islet insulin content.

Proinsulin and total protein biosynthesis
After culture, groups of 10 islets were incubated in 100 µl KRB medium containing 50 µCi/ml L-[4,5-3H]leucine and 27 mM glucose. Incubations were carried out at 37 C for 2 h in 95% O2-5% CO2 without shaking. The medium containing radioactive leucine was then carefully removed, and the islets were washed three times with Hanks’ solution containing 10 mM nonradioactive leucine. The washed islets were sonicated in 200 µl redistilled water (twice for 10 sec using a model B-12 sonifier at setting 4, Branson Ultrasonics Corp., Danbury, CT). The sonicates were centrifuged at 10,000 x g for 10 min at 4 C, and the supernatants were used for subsequent analysis. Proinsulin-insulin biosynthesis was measured by immunoprecipitation with undiluted antiinsulin serum in excess. Separation of bound from free insulin was achieved with protein A-Sepharose CL-4B, as previously described (24). Total protein synthesis was assessed from measurements of the radioactivity in the 10% trichloroacetic acid-precipitable fraction of the sonicates.

Total RNA and preproinsulin mRNA
Total RNA was prepared from 30 islets cultured in each condition as described by Chomczynski and Nicoletta (25). The total RNA content of the extracts was measured by spectrophotometry (1AOD260 = 40 µg/ml). The quantification of preproinsulin mRNA was achieved by a solution hybridization assay using a RNA probe radiolabeled with [35S]UTP (26). An in vitro synthesized 58-bp oligonucleotide corresponding to the last part of exon 3 of the rat preproinsulin II gene and flanked by BamHI and KpnI restriction sites was inserted into pGEM-3Zf(+). The resulting vector, prINS2, was linearized by EcoRI and transcribed in vitro with SP6 RNA polymerase in the presence of 3 µmol/L [35S]UTP for synthesis of the probe. Unlabeled sense RNA was obtained by transcription with T7 RNA polymerase after linearization with XbaI. The DNA template was removed by RQ1 deoxyribonuclease I, and transcripts were separated from unincorporated nucleotides on nick columns. Three serial dilutions of each RNA sample in 20 µl 0.2 x SET [1 x SET contains 1.0% SDS, 20 mM Tris-HCl (pH 7.5), and 10 mM EDTA] were mixed with 20 µl of 2 x hybridization solution (20,000 cpm probe, 1.2 M NaCl, 8 mM EDTA, 1.5 mM dithiothreitol, 50% formamide, and 40 mM Tris-HCl, pH 7.5). After hybridization at 70 C for 18 h, the samples were treated with 40 µg RNase A and 100 U RNaseT1 in the presence of 100 µg herring sperm DNA for 60 min at 37 C in a volume of 1 ml. Protected probe was precipitated with 100 µl 100% trichloroacetic acid. Precipitates were collected on glass fiber filters (GF/C), and the radioactivity was counted in a scintillation counter. Parallel hybridizations with increasing amounts of unlabeled sense RNA allowed construction of a standard curve. The amount of preproinsulin mRNA was calculated by comparison to the standard curve, and results were expressed as picograms of preproinsulin mRNA per µg total RNA.

Insulin assay
Insulin was measured by RIA using rat insulin as standard, monoiodinated porcine insulin as tracer, and antibody raised in our laboratory against porcine insulin. Antibody-bound insulin was separated from free insulin using Dextran T70-coated charcoal (27). For the determination of islet insulin contents, three islets were transferred into 200 µl acid-ethanol (0.18 M HCl in 95% ethanol). Insulin was extracted overnight at 4 C after sonication as previously described (28).

Presentation of results
All results are expressed as the mean ± SEM. Analysis between groups was carried out as appropriate by Student’s unpaired t test or one-way ANOVA with Student-Newman-Keuls’ test. P < 0.05 was considered significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Effects of glucose concentration during culture on subsequent insulin secretion
Islets cultured at 11 or 38 mM glucose retained significant responsiveness to glucose after both 1 and 6 weeks of culture (Table 1Go, lines 1–8). The response in absolute terms to 27 mM glucose postculture, however, was reduced in islets cultured at 38 mM glucose relative to that in islets cultured at 11 mM glucose. This difference was especially apparent after an overnight wash-out period (Table 1Go, lines 4 vs. 2 and 8 vs. 6). Glucose-induced insulin responses tended (nonsignificantly) to decrease between 1 and 6 weeks of culture (Table 1Go, lines 5–8 vs. 1–4). Such a tendency was seen when islets were cultured at both 11 and 38 mM glucose.


View this table:
[in this window]
[in a new window]
 
Table 1. Insulin release after 1 or 6 weeks of culture

 
Islet survival and islet volume
Data on islet survival are given in the text only. Islet survival after 6 weeks of culture was high under all experimental conditions (80.9% in 11 mM glucose, 78.0% in 11 mM glucose with 0.1 mM AG, 80.9% in 38 mM glucose, 81.9% in 38 mM glucose with 0.1 mM AG, and 83.7% in 38 mM glucose with 1 mM AG, respectively; mean of three experiments).

Islet volume was increased by high glucose during culture (Table 2Go). Although mean values of islet volumes were somewhat larger after AG, there was not a significant effect (P > 0.3).


View this table:
[in this window]
[in a new window]
 
Table 2. Islet volume and culture conditions

 
AGEs-associated fluorescence (Fig. 1Go)
The presence of AGEs was estimated by fluorescence measurements. After 1 week of culture, fluorescence did not differ among 5.5, 11, or 38 mM glucose-cultured islets. AG did not affect fluorescence under these conditions. Between 1 and 3 weeks, fluorescence markedly increased in islets cultured at 38 mM glucose compared with that in 5.5 or 11 mM glucose-cultured islets. The fluorescence in 38 mM glucose-cultured islets increased further after 6 weeks of culture. The increase in fluorescence was significantly (P < 0.01) diminished by 0.1 and 1 mM AG.



View larger version (25K):
[in this window]
[in a new window]
 
Figure 1. Islet fluorescence after 1–6 weeks of culture. Batches of 20 islets were used to measure fluorescence as described in Materials and Methods. Data are the mean ± SEM of 10 observations. *, P < 0.001 vs. measurements from islets cultured at 11 mM glucose; {ddagger}, P < 0.05 vs. measurements at 38 mM glucose without AG at each culture period; §, P < 0.01 vs. measurements at 38 mM glucose without AG after 3 weeks.

 
Effects of AG on insulin accumulation in culture medium
The presence of AG during culture lowered insulin concentrations in high glucose culture medium to a moderate extent (Table 3Go). The effect seemed dose dependent, as 1 mM AG exerted a more pronounced effect than 0.1 mM. The inhibitory effect was not appreciably altered by the time of exposure to AG (1, 3, or 6 weeks; Table 3Go).


View this table:
[in this window]
[in a new window]
 
Table 3. Accumulation of insulin in culture medium

 
Effects of 1 week of AG treatment on insulin release
The effects of AG on glucose-induced insulin secretion were tested before as well as after a 24-h wash-out period in the absence of the drug. After the wash-out, culture with AG for 1 week together with 11 mM glucose failed to affect subsequent glucose-induced insulin secretion (+53 ± 56% increment of release at 3.3 mM glucose; +21 ± 9% increment of release at 27 mM glucose). Similarly, the previous presence of AG together with 38 mM glucose was without a significant effect on subsequent insulin secretion (-13 ± 1% increment of release at 3.3 mM glucose; +4 ± 12% increment of release at 27 mM glucose). A wash-out period did not have any clear effect of previous AG treatment (Fig. 2Go, upper graphs).



View larger version (22K):
[in this window]
[in a new window]
 
Figure 2. Effects of AG on insulin release after 1 and 6 weeks of culture followed by a wash-out procedure. Insulin release was measured in 60-min final incubations after 24 h of extended culture in the absence of AG and in the presence of 11 mM glucose. Data are the mean ± SEM of 10–20 observations. *, P < 0.05 vs. the value without AG.

 
Effects of 6 weeks of AG treatment on insulin release
The presence of AG during 6 weeks of culture failed to positively affect insulin secretion. There was, in fact, a negative influence on release at 3.3 mM glucose after culture with both 11 mM glucose (-17 ± 9%) and 38 mM glucose (Fig. 3Go).



View larger version (26K):
[in this window]
[in a new window]
 
Figure 3. Effects of AG on insulin release from 6-week 38 mM glucose-cultured islets in response to various secretagogues. Insulin release was measured as described in Fig. 2Go. Data are the mean ± SEM of 10 observations. *, P < 0.05 vs. the value without AG.

 
Release at 27 mM glucose was not significantly inhibited after AG and 11 mM glucose treatment (-16 ± 7%), whereas it was inhibited after AG and 38 mM glucose treatment (Fig. 3Go). Under the same conditions, AG tended to inhibit arginine- and isobutylmethylxanthine-induced insulin secretion (Fig. 3Go).

The effects of AG after wash-out are shown in Fig. 2Go, lower graphs. When cocultured with 11 mM glucose, AG did not affect basal or glucose-stimulated insulin release after wash-out. In contrast, when AG was cocultured with 38 mM glucose, both basal and glucose-stimulated insulin release were markedly and significantly increased.

Effects of AG on proinsulin and total protein biosynthesis
Six weeks of culture with 38 mM glucose enhanced both proinsulin and total protein synthesis relative to culture with 11 mM glucose (Fig. 4Go, upper graphs). AG enhanced both proinsulin synthesis and total protein synthesis in 38 mM, but not in 11 mM, cultured islets. A wash-out period eliminated the enhancing effect of 38 vs. 11 mM glucose-cultured islets on biosynthesis (Fig. 4Go, lower graphs). However, the effect of previous exposure to AG persisted with regard to both proinsulin and total protein synthesis.



View larger version (33K):
[in this window]
[in a new window]
 
Figure 4. Effects of AG on proinsulin and 6 weeks of total protein biosynthesis in islets after culture (upper graphs) or after an additional 24-h culture with 11 mM glucose only (lower graphs). Proinsulin synthesis is presented in the left columns, and total protein synthesis is shown in the right columns. Data are the mean ± SEM of 10 observations. *, P < 0.05 vs. the value without AG.

 
Effects of AG on total RNA and preproinsulin mRNA
The total RNA content in 6-week 38 mM glucose-cultured islets was 2.8 ± 0.39 µg/30 islets and significantly (P < 0.05) higher than that in 11 mM glucose-cultured islets (1.69 ± 0.14 µg/30 islets). This increase was not significantly affected by previous AG treatment (2.71 ± 0.42 µg/30 islets in 0.1 mM AG and 1.9 ± 0.24 µg/30 islets in 1 mM AG).

Preproinsulin mRNA was also measured at the end of a 6-week culture period (Fig. 5Go). Preproinsulin mRNA was expectedly higher after culture with 11 or 38 mM glucose than after culture with 5.5 mM glucose. The coexistence of AG with 38 mM glucose enhanced levels of preproinsulin mRNA. The increase was 53% with 0.1 mM AG and 94% with 1 mM AG.



View larger version (36K):
[in this window]
[in a new window]
 
Figure 5. Effects of AG on preproinsulin mRNA content in islets after 6 weeks of culture. Preproinsulin mRNA was determined by solution hybridization as described in Materials and Methods. Data are the mean ± SEM of 10 observations. *, P < 0.05 vs. the value without AG.

 
Effects of AG on islet insulin content
Before wash-out, previous AG treatment failed to significantly affect islet insulin content (Table 4Go). The lack of effect was seen after both 1 and 6 weeks of culture and in the presence of both 11 and 38 mM glucose. The effect of a wash-out period was to increase insulin content in islets previously cultured with AG and 38 mM glucose.


View this table:
[in this window]
[in a new window]
 
Table 4. Effects of AG on islet insulin content

 
Effects of L-NMA on insulin release
After 1 week of treatment with L-NMA, stimulated insulin release from 11 mM glucose-cultured islets was suppressed (from 10.4 ± 1.03 to 4.61 ± 0.41 ng/islet·60 min; P < 0.001), as was basal secretion from 38 mM glucose-cultured islets (from 3.33 ± 0.29 to 2.17 ± 0.12 ng/islet·60 min; P < 0.001). Six weeks of culture with L-NMA and 38 mM glucose led to increased basal insulin release (from 1.09 ± 0.08 to 2.31 ± 0.37 ng/islet·60 min; P < 0.05), but had no effect on stimulated insulin release. No enhancement of insulin release was observed following previous L-NMA treatment after wash-out of islets cultured for a period of 1 or 6 weeks.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The negative effects of hyperglycemia can readily be demonstrated in vivo and subsequently in vitro (2, 4, 5). It has proven more difficult to induce negative effects by high glucose in vitro. This partial discrepancy is probably not due to the absence of a "toxic" effect of glucose in vitro, but, rather, to a different balance between positive and negative effects of glucose in vivo vs. in vitro. Glucose is normally the main stimulator of B cell secretion, biosynthesis, and replication. Some of those stimulatory effects undoubtedly persist even under conditions when negative effects overshadow positive ones. The positive effects of glucose may be stronger in isolated islets in vitro than during in vivo conditions because of the potential diffusion problem during culture. Hence, oxygenation of the interior of islets may not be optimal under these conditions (29). High glucose could then, by acting as substrate for glycolysis, partly substitute for decreased aerobic metabolism. Such a mechanism may explain the larger islets (volume and RNA) after culture with 38 mM glucose than with lower glucose concentrations.

Nevertheless, our results indicate that B cell secretory potential was decreased after culture with high glucose. Hence, although a fold increase in secretion due to 27 mM glucose was not affected, the absolute insulin responses were decreased after culture with 38 vs. 11 mM glucose. Notably, this decrease in insulin response was most apparent after wash-out. This indicates that the decrease reflects a lasting negative effect of high glucose exposure.

Two lines of evidence support a role for AGE formation on B cell function. The first one pertains to fluorescence measurements. These measurements document a time- and glucose-dependent increase in islet fluorescence during conditions of measurement that have, in other tissues, been shown to reflect the contents of AGE. Furthermore, increased fluorescence could partly be inhibited by AG. The second line of evidence pertains to effects of AG on B cell function, and these effects are discussed below.

Both inhibitory and stimulatory effects of AG were observed. The inhibitory effects of AG on insulin release under some conditions are in line with previous reports. Inhibition by AG was thus found during short term incubation with the drug (14) or after 2 days of islet culture with AG (17). It has been proposed that an inhibitory effect of AG could be due to intracellular acidification by the drug (14). However, the precise mechanism behind inhibition has not been elucidated.

The stimulatory effects of AG on insulin secretion were apparent after a wash-out procedure that consisted of an additional 24-h culture period at 11 mM glucose in the absence of the drug. The stimulatory effect of AG on basal and glucose-induced insulin secretion was dependent on the period of high glucose exposure preceding wash-out. The stimulatory effect of previous AG treatment was thus apparent after 6 weeks, but not after 1 week, of culture. We interpret the wash-out effect to mean that a long term stimulatory effect by AG can be unmasked by removing a negative effect of ambient AG on secretion. Islets not subjected to a wash-out period were indeed washed in KRB before final incubations. However, this procedure most likely did not remove AG completely from islets due to a delay in diffusion of the drug from the interior of islets and cells.

The beneficial effects of AG on protein biosynthesis were also apparent in 6-week high glucose-cultured islets. In contrast to the effects of AG on insulin secretion, an enhancing effect on [3H]leucine accumulation into proinsulin and total protein synthesis was apparent both before and after wash-out. A beneficial effect of AG on insulin biosynthesis agrees well with our data on the islet content of preproinsulin mRNA obtained immediately after culture. Thus, previous exposure to AG markedly increased the islet content of preproinsulin mRNA.

The available evidence indicates that the beneficial effects of AG on insulin secretion and biosynthesis are due to prevention of AGE formation in islets. A multitude of studies have shown that AG prevents the formation of AGE in other tissues and that such effects prevent tissue damage (10, 11, 12, 13). Furthermore, our assessment of AGE formation in islets indicates that AG inhibits AGE formation in islets. Moreover, our data argue against the alternative explanation, that AG exerts its stimulatory effects through inhibition of nitric oxide (NO) synthase. The time dependency for the stimulatory effects of AG speaks against involvement of NO synthase, as inhibitory effects of AG on this enzyme are immediate and not time dependent (18, 19). Also, the effects of AG on insulin biosynthesis persisted after a 24-h wash-out period. Furthermore, a specific inhibitor of NO synthase, present during 6 weeks of culture, failed to reproduce the effects of AG.

Granted that the beneficial (stimulatory) effects of AG are linked to the prevention of AGE formation, it is not known which aspects of formation exert negative effects on B cell function. Multiple proteins of importance for the secretory process could be affected as well as molecules of importance for transcription and translation (30, 31). A role for altered transcription factors would be compatible with the influences on protein synthesis and insulin mRNA presently found. Further research is needed to elucidate these uncertainties.

Our results could be important for the future treatment of patients with noninsulin-dependent diabetes mellitus. Insulin secretion in these patients deteriorates with the duration of the disease (32); this could in part be due to glucotoxicity. Our results indicate a role for islet AGE formation in glucotoxicity. Theoretically, AGE formation could be even more important than indicated by our results, as a negative effect of circulating AGE on B cells was not tested and therefore cannot be ruled out. In this context it should be mentioned that we have also performed in vivo studies showing a beneficial effect of AG on islet graft function in a rat transplantation model (33). If AGE formation plays a role in glucotoxicity toward B cells, it may be possible to treat patients with drugs such as AG to avoid or retard the deterioration of B cell function.

In conclusion, our results provide evidence for glucose-induced formation of AGEs in pancreatic islets and for the inhibition of such formation by AG. Moreover, in high glucose-cultured islets, AG time-dependently increases B cell secretion and insulin biosynthesis. These observations indicate a negative role of AGEs in B cell function.


    Footnotes
 
1 This work was supported by the Swedish Medical Research Council (Grant 19X-04540), the Norwegian Research Council (Grant 111282/310), the Swedish Diabetes Association, the Nordic Insulin Foundation, and Funds of the Karolinska Institute. Back

Received July 3, 1996.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Weir GC, Leahy JL, Bonner-Weir S 1986 Experimental reduction of ß-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 2:125–161[Medline]
  2. Leahy JL, Cooper HE, Deal DA, Weir GC 1986 Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions. J Clin Invest 77:908–915
  3. Palmer JP, Benson JW, Walter RM, Ensinck JW 1976 Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest 58:565–570
  4. Leahy JL 1990 Natural history of ß-cell dysfunction in NIDDM. Diabetes Care 13:992–1010[Abstract]
  5. Sako Y, Grill V 1990 A 48 h lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127:1580–1589[Abstract]
  6. Sako Y, Grill V 1990 Coupling of ß-cell desensitization by hyperglycaemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 39:1580–1583[Abstract]
  7. Brownlee M, Cerami A, Vlassara H 1988 Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321[Medline]
  8. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A 1986 Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629–1632[Abstract/Free Full Text]
  9. Brownlee M 1994 Glycation and diabetic complications. Diabetes 43:836–841[Medline]
  10. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M 1991 Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555–11558[Abstract/Free Full Text]
  11. Soules-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G 1991 Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40:1328–1335[Abstract]
  12. Cameron NE, Cotter MA, Dines K, Love A 1992 Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35:946–950[CrossRef][Medline]
  13. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA 1991 Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology and oxygen free radicals. Proc Natl Acad Sci USA 88:6107–6111[Abstract/Free Full Text]
  14. Zähner D, Malaisse WJ 1992 Effects of advanced glycation products and aminoguanidine upon insulin release. Diabetes Nutr Metab 5:43–46
  15. Edelstein D, Brownlee M 1992 Mechanistic studies of advanced glycation end product inhibition by aminoguanidine. Diabetes 41:26–29[Abstract]
  16. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW 1994 Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanism, and inhibition of late stages of the Maillard reaction. Diabetes 43:676–683[Abstract]
  17. Tasaka Y, Nakaya F, Matsumoto H, Omori Y 1994 Effects of aminoguanidine on insulin release from pancreatic islets. Endocr J 41:309–313[Medline]
  18. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster Jr JR, Williamson JR, McDaniel ML 1992 Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552–556[Abstract]
  19. Tilton RG, Chang K, Hasan KS, Smith SR, Perrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR 1993 Prevention of diabetic vascular dysfunction by guanidines–inhibition of nitric oxide synthase vs. advanced glycation end-product formation. Diabetes 42:221–232[Abstract]
  20. Lacy PE, Kostianovsky M 1967 Method for the isolation of intact islets of Langerhans from the pancreas. Diabetes 16:35–39[Medline]
  21. Monnier VM, Kohn RH, Cerami A 1984 Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 81:583–587[Abstract/Free Full Text]
  22. Östenson C-G, Grill V 1987 Evidence that hyperglycemia increases muscarinic binding in pancreatic islets of the rat. Endocrinology 121:1705–1710[Abstract]
  23. Umbreit WW, Burris RH, Stauffer JF 1957 Manometric Techniques. Burgess, Minneapolis, pp 149–150
  24. Halban PA, Wollheim CB, Blondel B, Renold AE 1980 Long-term exposure of isolated pancreatic islets to mannoheptulose: evidence for insulin degradation in the ß-cell. Biochem Pharmacol 29:2625–2633[CrossRef][Medline]
  25. Chomczynski P, Nicoletta S 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorform extraction. Anal Biochem 162:156–159[Medline]
  26. Möller C, Arner P, Sonnenfeld T, Norstedt G 1991 Quantitative comparison of insulin-like growth factor mRNA levels in human and rat tissues analysed by solution hybridization assay. J Mol Endocrinol 7:213–222[Abstract/Free Full Text]
  27. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ 1965 Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375–1384[Medline]
  28. Grill V, Rundfeldt M, Efendic S 1981 Previous exposure to glucose enhances somatostatin secretion from the isolated perfused rat pancreas. Diabetologia 30:495–500
  29. Dionne KE, Colton CK, Yarmush ML 1993 Effect of hypoxia on insulin secretin by isolated rat and canine islets of Langerhans. Diabetes 42:12–21[Abstract]
  30. Olson LK, Redmon JB, Towle HC, Robertson RP 1993 Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest 92:514–519
  31. Robertson PR, Olson KL, Zhang H-J 1994 Differentiating glucose toxicity from glucose desensitization: a novel message from the insulin gene. Diabetes 43:1085–1089[Abstract]
  32. UK Prospective Diabetes Study Group 1995 U.K. prospective diabetes study 16. Overview of 6 year’s therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258[Abstract]
  33. Inoue K, Norgren S, Luthman H, Grill V Chronic hyperglycemia induces defects in B-cell functioning which are ameliorated by aminoguanidine. 15th IDF Congress, Kobe, Japan, 1994 (Abstract 105)



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. Cassese, I. Esposito, F. Fiory, A. P. M. Barbagallo, F. Paturzo, P. Mirra, L. Ulianich, F. Giacco, C. Iadicicco, A. Lombardi, et al.
In Skeletal Muscle Advanced Glycation End Products (AGEs) Inhibit Insulin Action and Induce the Formation of Multimolecular Complexes Including the Receptor for AGEs
J. Biol. Chem., December 26, 2008; 283(52): 36088 - 36099.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K. Maedler, F. T. Schulthess, C. Bielman, T. Berney, C. Bonny, M. Prentki, M. Y. Donath, and R. Roduit
Glucose and leptin induce apoptosis in human {beta}-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases
FASEB J, June 1, 2008; 22(6): 1905 - 1913.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. Poitout and R. P. Robertson
Glucolipotoxicity: Fuel Excess and {beta}-Cell Dysfunction
Endocr. Rev., May 1, 2008; 29(3): 351 - 366.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
S. Kooptiwut, M. Kebede, S. Zraika, S. Visinoni, K. Aston-Mourney, J. Favaloro, C. Tikellis, M. C Thomas, J. M Forbes, M. E Cooper, et al.
High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction
J. Mol. Endocrinol., August 1, 2005; 35(1): 39 - 48.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Peppa, C. He, M. Hattori, R. McEvoy, F. Zheng, and H. Vlassara
Fetal or Neonatal Low-Glycotoxin Environment Prevents Autoimmune Diabetes in NOD Mice
Diabetes, June 1, 2003; 52(6): 1441 - 1448.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
I. Maestre, J. Jordan, S. Calvo, J. A. Reig, V. Cena, B. Soria, M. Prentki, and E. Roche
Mitochondrial Dysfunction Is Involved in Apoptosis Induced by Serum Withdrawal and Fatty Acids in the {beta}-Cell Line Ins-1
Endocrinology, January 1, 2003; 144(1): 335 - 345.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky
Are Oxidative Stress-Activated Signaling Pathways Mediators of Insulin Resistance and {beta}-Cell Dysfunction?
Diabetes, January 1, 2003; 52(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Endocr. Rev., October 1, 2002; 23(5): 599 - 622.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
V. Poitout and R. P. Robertson
Minireview: Secondary {beta}-Cell Failure in Type 2 Diabetes--A Convergence of Glucotoxicity and Lipotoxicity
Endocrinology, February 1, 2002; 143(2): 339 - 342.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Biarnes, M. Montolio, V. Nacher, M. Raurell, J. Soler, and E. Montanya
{beta}-Cell Death and Mass in Syngeneically Transplanted Islets Exposed to Short- and Long-Term Hyperglycemia
Diabetes, January 1, 2002; 51(1): 66 - 72.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Tanaka, C. E. Gleason, P. O. T. Tran, J. S. Harmon, and R. P. Robertson
Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants
PNAS, September 14, 1999; 96(19): 10857 - 10862.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Koyama, R.-i. Wada, H. Sakuraba, H. Mizukami, and S. Yagihashi
Accelerated Loss of Islet ß Cells in Sucrose-Fed Goto-Kakizaki Rats, a Genetic Model of Non-Insulin-Dependent Diabetes Mellitus
Am. J. Pathol., August 1, 1998; 153(2): 537 - 545.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tajiri, Y.
Right arrow Articles by Grill, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tajiri, Y.
Right arrow Articles by Grill, V.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals